Stephen M Mahler
Australian Institute for Bioengineering and Nanotechnology, University of Queensland, Australia
Biography
Stephen Mahler is a Senior Group Leader at the Australian Institute for Bioengineering and Nanotechnology and Director of the ARC Training Centre for Biopharmaceutical Innovation at the University of Queensland. His expertise is in the discovery, research and development of biologic medicines, particularly engineered monoclonal antibodies. His recent research endeavors include targeting nanoparticles using bispecific antibodies. He has a number of collaborations with key biotechnology companies in Australia and internationally, and was part of the team at Cambridge Antibody Technology, UK that developed the technology for the development of the TNF antagonist Humira, now the largest selling drug globally. He has particular interest in translating new biologics and nanomedicines to the clinic, and has been associated with a number of biologics entering clinical development.